142 related articles for article (PubMed ID: 35567091)
41. Formulation of a Novel Hesperetin-Loaded Nanoemulsion and Its Promising Effect on Osteogenesis.
Mancim-Imbriani MJ; Duarte JL; Di Filippo LD; Durão LPL; Chorilli M; Palomari Spolidorio DM; Maquera-Huacho PM
Pharmaceutics; 2024 May; 16(6):. PubMed ID: 38931821
[TBL] [Abstract][Full Text] [Related]
42. Development of engineered transferosomal gel containing meloxicam for the treatment of osteoarthritis.
Maheshwari R; Sharma M; Chidrawar VR
Ann Pharm Fr; 2024 Apr; ():. PubMed ID: 38657858
[TBL] [Abstract][Full Text] [Related]
43. Development of a Nanoemulgel for the Topical Application of Mupirocin.
Alhasso B; Ghori MU; Conway BR
Pharmaceutics; 2023 Sep; 15(10):. PubMed ID: 37896147
[TBL] [Abstract][Full Text] [Related]
44. Green Nanotechnology in the Formulation of a Novel Solid Dispersed Multilayered Core-Sheath Raloxifene-Loaded Nanofibrous Buccal Film; In Vitro and In Vivo Characterization.
Nageeb El-Helaly S; Abd-Elrasheed E; Salim SA; Fahmy RH; Salah S; El-Ashmoony MM
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33915828
[TBL] [Abstract][Full Text] [Related]
45. Matrix-mini-tablets of lornoxicam for targeting early morning peak symptoms of rheumatoid arthritis.
Mohd AH; Raghavendra Rao NG; Avanapu SR
Iran J Basic Med Sci; 2014 May; 17(5):357-69. PubMed ID: 24967065
[TBL] [Abstract][Full Text] [Related]
46. Transdermal Drug Delivery System of Linagliptin Sustained-release Microparticle Gels: In vitro Characterization and In vivo Evaluation.
Liu J; Guo S; Hong S; Piao J; Piao M
Curr Drug Deliv; 2024 Jan; ():. PubMed ID: 38243939
[TBL] [Abstract][Full Text] [Related]
47. New, Biocompatible, Chitosan-Gelled Microemulsions Based on Essential Oils and Sucrose Esters as Nanocarriers for Topical Delivery of Fluconazole.
Vlaia L; Olariu I; Muţ AM; Coneac G; Vlaia V; Anghel DF; Maxim ME; Stângă G; Dobrescu A; Suciu M; Szabadai Z; Lupuleasa D
Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056971
[TBL] [Abstract][Full Text] [Related]
48. Long-Acting Paliperidone Parenteral Formulations Based on Polycaprolactone Nanoparticles; the Influence of Stabilizer and Chitosan on In Vitro Release, Protein Adsorption, and Cytotoxicity.
Elmowafy M; Alruwaili NK; Shalaby K; Alharbi KS; Altowayan WM; Ahmad N; Zafar A; Elkomy M
Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32079093
[TBL] [Abstract][Full Text] [Related]
49. Sustainable Alternatives to Petroleum-Derived Excipients in Pharmaceutical Oil-in-Water Creams.
Gates D; Badruddoza AZM; Zahid MI; Yeoh T; Shah J; Walsh T; Nurunnabi M
AAPS PharmSciTech; 2024 Mar; 25(4):68. PubMed ID: 38538866
[TBL] [Abstract][Full Text] [Related]
50. Ionically Crosslinked Complex Gels Loaded with Oleic Acid-Containing Vesicles for Transdermal Drug Delivery.
Lai WF; Tang R; Wong WT
Pharmaceutics; 2020 Aug; 12(8):. PubMed ID: 32748814
[TBL] [Abstract][Full Text] [Related]
51. Solubility of Poorly Soluble Drugs in Phosphatidylcholine-Based Drug Delivery Systems: Comparison of the Loading Capacity in the Bulk Formulation and Its Dispersed State.
Grüne L; Bunjes H
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543186
[TBL] [Abstract][Full Text] [Related]
52. Novel Therapeutic Hybrid Systems Using Hydrogels and Nanotechnology: A Focus on Nanoemulgels for the Treatment of Skin Diseases.
Sghier K; Mur M; Veiga F; Paiva-Santos AC; Pires PC
Gels; 2024 Jan; 10(1):. PubMed ID: 38247768
[TBL] [Abstract][Full Text] [Related]
53.
Alam P; Imran M; Ali A; Majid H
Gels; 2024 Apr; 10(5):. PubMed ID: 38786220
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the Potential of Chitosan Nanoparticles as a Delivery Vehicle for Gentamicin for the Treatment of Osteomyelitis.
Simpson E; Sarwar H; Jack I; Lowry D
Antibiotics (Basel); 2024 Feb; 13(3):. PubMed ID: 38534643
[TBL] [Abstract][Full Text] [Related]
55. Formulation of silymarin surface modified vesicles: In vitro characterization to cell viability assessment.
Imam SS; Alshammari SO; Alshehri S; Mahdi WA; Al-Agamy MH
Saudi Pharm J; 2024 Jun; 32(6):102072. PubMed ID: 38726227
[TBL] [Abstract][Full Text] [Related]
56. Strategies to Improve the Transdermal Delivery of Poorly Water-Soluble Non-Steroidal Anti-Inflammatory Drugs.
Balmanno A; Falconer JR; Ravuri HG; Mills PC
Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794337
[TBL] [Abstract][Full Text] [Related]
57. Stimuli-Responsive Polymers for Transdermal, Transmucosal and Ocular Drug Delivery.
Berillo D; Zharkinbekov Z; Kim Y; Raziyeva K; Temirkhanova K; Saparov A
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959332
[TBL] [Abstract][Full Text] [Related]
58. Transdermal Drug Delivery of Tazarotene: Determining Tazarotene's Potential in Local Transdermal Therapy.
Hamzehpour H; Óskarsdóttir Á; Jónsson H; Jónsdóttir F; Sigurjónsson ÓE; Snorradottir BS
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258075
[TBL] [Abstract][Full Text] [Related]
59. Formulation of Ascorbic Acid and Betaine-based Therapeutic Deep Eutectic System for Enhanced Transdermal Delivery of Ascorbic Acid.
Song JE; Jun SH; Ryoo JY; Kang NG
Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794349
[TBL] [Abstract][Full Text] [Related]
60. Nanotechnology-Based Biopolymeric Oral Delivery Platforms for Advanced Cancer Treatment.
Chivere VT; Kondiah PPD; Choonara YE; Pillay V
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32102429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
